Status:

Do Not Prescribe (DNP), Red

Decision Date:

October 2021

Comments

RED:

• NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis.
• NICE TA916: Bimekizumab for treating active psoriatic arthritis. ICB commissioned (decision date November 2023)
• NICE TA918: Bimekizumab for treating axial spondyloarthritis. ICB commissioned (decision date November 2023)

 DNP:  NICE TA1028: (Terminated appraisal) Bimekizumab for treating moderate to severe hidradenitis suppurativa (decision date Feb 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again